Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure

Официальное название

Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure in Patients With Persistent Atrial Fibrillation: a Randomized, Multicentric, and Comparative Study

Обзор

This study aims at assessing whether electric cardioversion can act as a discriminant factor between patients requiring Pulmonary Vein Isolation (PVI) procedure alone or PVI procedure combined with substrate modulation. All included patients will undergo an electric cardioversion, then: * Patients with electric cardioversion success will be treated as per Standard of Care and according to ESC recommendations (2020). A prospective registry will be implemented for these patients. * Patients with electric cardioversion failure will be randomized in the study between 2 ablative procedures: * PVI procedure alone * PVI procedure combined with substrate modulation

Подробное описание

Atrial fibrillation (AF) is the most common heart rhythm disorder. It is the result of uncoordinated action of the atrial myocardial cells, causing rapid and irregular contraction of the heart's atria.

The AF prevalence in adults is currently estimated to be between 2% and 4% and is expected to increase by a factor of 2.3 in the next few years, due to the increased longevity of the general population and the increased search for undiagnosed AF. Increased age is an important risk factor for AF, but other increased comorbidities, including hypertension, diabetes, heart failure, coronary artery disease, chronic renal failure, obesity, and obstructive sleep apnoea syndrome, are also important; modifiable risk factors contribute strongly to the development and progression of AF (ESC Guideline, 2020).

The European Society of Cardiology (ESC) recommended pulmonary vein isolation (PVI) (Class IA) as first-line ablative strategy for persistent AF (Class IA) (ESC Guideline, 2020). However, PVI alone is only effective in treating about 40% to 60% of patients with persistent AF in the general population (unselected). If we apply this strategy to all patients (PVI alone), we accept to re-do ablative procedure in up to 60% of patients.

The second feasible strategy is to treat patients with persistent AF by PVI combined with substrate modulation (ESC Class IIb). This strategy, when done well, by creating irreversible lesions (Marshall-PLAN) can effectively treat 70% to 80% of AF patients. But this implies that the investigator will be doing unnecessary substrate modulation in up to 40% of patients, which can lead to increased risks associated with the ablative procedure, longer procedure times, multiple lesions, etc… In addition, incorrect or incomplete substrate modulation is pro-arrhythmic and leads to recurrences in the form of left atrial flutters, tolerance of which, is generally poor.

Both ablative strategies have been widely validated in large numbers of published studies.

The problem is to know when and for which patients to apply one or the other of the two strategies. Electric cardioversion could help in selecting the most appropriate strategy.

Вмешательства

• Процедура Pulmonary Vein Isolation (PVI) alone
  PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
• Процедура PVI procedure associated with substrate modulation
  PVI procedure associated with substrate modulation

Первичные конечные точки

• 1-year sinus rhythm maintenance rate [Срок оценки: At 1 year after ablation]

Вторичные конечные точки (12)

• Rate of patients with sinus rhythm (randomized patients) [Срок оценки: At 1 year after ablation]
• Rate of patients with sinus rhythm (registry patients) [Срок оценки: At 1 year after ablation]
• Rate of patients with sinus rhythm (randomized and registry patients, strategy PVI procedure alone) [Срок оценки: At 1 year after ablation]
• Duration (in minutes) of ablative procedure [Срок оценки: On the day of the ablative procedure]
• Duration (in minutes) of radiofrequency use [Срок оценки: On the day of the ablative procedure]
• Duration (in minutes) of Fluoroscopy [Срок оценки: On the day of the ablative procedure]
• Duration (in days) of hospitalization [Срок оценки: From date of surgery until the date of discharge from hospital assessed up to 1 day]
• Evaluation of major complications rate [Срок оценки: Up to 1 year]
• Evaluation of drug treatment use rate or electric cardioversion in the blanking period [Срок оценки: At three months after ablation]
• Evaluation of the minor complications rate between the two strategies after 1-year follow-up (randomized patients) [Срок оценки: up to 1-year follow-up]
• Evaluation of the vein isolation as well as other linear lesions in patients with recurrence of atrial fibrillation during 1 year after ablation [Срок оценки: up to 1-year follow-up]
• Evaluation of the impact of low voltage areas on the response to EC prior to catheter ablation [Срок оценки: catheter ablation]

Критерии участия

Критерии включения

Criteria to be validated for patients included before performing electric cardioversion:

1\) Persistent AF (continuous for at least 7 days without interruption according to information transmitted by the cardiologist and the patient), symptomatic and resistant to at leat one anti-arrhythmic drug treatment including amiodarone;

Criteria to be validated for patients included after performing electric cardioversion :

• Patient treated by electric cardioversion for persistent AF, symptomatic and resistant to anti-arrhythmic treatment including amiodarone and whom ablative procedure is planned in the following 4-6 weeks after electric cardioversion

Criteria to be validated for all patients included:

• Life expectancy > 5 years;
• Female or male between 18 and 80 years of age at the electric cardioversion time
• Affiliation to a health insurance system;
• Patient informed of the study and having signed informed consent

Criteria to be validated prior to randomization on the day of ablation (these patients may be randomized):

• Patient with failed electric cardioversion i.e. in AF, confirmed by ECG.

Критерии исключения

Criteria to be validated before or after performing electric cardioversion (the study cannot be proposed to patients corresponding to these criteria):

• Current hyperthyroidism;
• Pregnant or breastfeeding woman;
• Patient with a Body Mass Index (BMI) greater than 35;
• Patient with severe Chronic Obstructive Pulmonary Disease (COPD);
• Patient with hypertrophic heart disease;
• Patient with a mechanical or biological mitral valve;
• Contraindications to anticoagulants;
• Transient Ischemic Attack (TIA) /stroke less than 6 months old;
• Psychiatric illness affecting follow-up;
• Left Ventricular Ejection Fraction (LVEF) < 40% ;
• Uncontrolled ischaemic heart disease (angina, myocardial ischaemia)
• Patients under legal protection
• Cardiac surgery on left atrium
• Inflammatory status in progress (cancer, rheumatoid arthritis, PPRZ, acute or chronic periodontitis, Crohn's disease, RCUH)
• Pulmonary embolism or phlebitis less than 6 months old
• Prior atrial fibrillation ablation
• Active cancer

Criteria to be validated before randomization, on the day of ablation (these patients cannot be randomized):

• Patient in sinus rhythm 4-6 weeks after electric cardioversion: these patients are included in the study registry.
• Patient with complete absence of sinus rhythm (less than 10 seconds) after 3 electric cardioversion attempts: these patients will discontinue from the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Франция · 13 центров

• Infirmerie Protestante — Caluire-et-Cuire
• CH Libourne — Libourne
• CHU Lille — Lille
• Hopital ST Phillbert — Lomme
• CMC Ambroise Paré Hartmann — Neuilly-sur-Seine
• Hôpital Privé Les Franciscaines — Nîmes
• Hôpital Européen Georges Pompidou Service de cardiologie - Unité rythmologie — Paris
• Clinique St Pierre Cardiologie — Perpignan
• … и ещё 5 центров

Публикации

• Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaborati PMID 34520521
• Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 May 7;372(19):1812-22. doi: 10.1056/NEJMoa1408288. PMID 25946280
• Sanders P, Hocini M, Jais P, Sacher F, Hsu LF, Takahashi Y, Rotter M, Rostock T, Nalliah CJ, Clementy J, Haissaguerre M. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome. Eur Heart J. 2007 Aug;28(15):1862-71. doi: 10.1093/eurheartj/ehl548. PMID 17341503
• Knecht S, Hocini M, Wright M, Lellouche N, O'Neill MD, Matsuo S, Nault I, Chauhan VS, Makati KJ, Bevilacqua M, Lim KT, Sacher F, Deplagne A, Derval N, Bordachar P, Jais P, Clementy J, Haissaguerre M. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J. 2008 Oct;29(19):2359-66. doi: 10.1093/eurheartj/ehn302. Epub 2008 Jul 8. PMID 18614522
• Valderrabano M, Peterson LE, Bunge R, Prystash M, Dave AS, Nagueh S, Kleiman NS. Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design. Am Heart J. 2019 Sep;215:52-61. doi: 10.1016/j.ahj.2019.04.022. Epub 2019 May 11. PMID 31279972
• Kim DT, Lai AC, Hwang C, Fan LT, Karagueuzian HS, Chen PS, Fishbein MC. The ligament of Marshall: a structural analysis in human hearts with implications for atrial arrhythmias. J Am Coll Cardiol. 2000 Oct;36(4):1324-7. doi: 10.1016/s0735-1097(00)00819-6. PMID 11028490
• Valderrabano M, Chen HR, Sidhu J, Rao L, Ling Y, Khoury DS. Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans. Circ Arrhythm Electrophysiol. 2009 Feb;2(1):50-6. doi: 10.1161/CIRCEP.108.818427. PMID 19756206
• Dave AS, Baez-Escudero JL, Sasaridis C, Hong TE, Rami T, Valderrabano M. Role of the vein of Marshall in atrial fibrillation recurrences after catheter ablation: therapeutic effect of ethanol infusion. J Cardiovasc Electrophysiol. 2012 Jun;23(6):583-91. doi: 10.1111/j.1540-8167.2011.02268.x. Epub 2012 Mar 19. PMID 22429895

Идентификаторы

NCT: NCT05264831 · PACIFIC · 2021-A02291-40

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗